<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078962</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02577</org_study_id>
    <secondary_id>03-06</secondary_id>
    <secondary_id>U01CA069853</secondary_id>
    <secondary_id>CDR0000353204</secondary_id>
    <nct_id>NCT00078962</nct_id>
  </id_info>
  <brief_title>GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination With Gemcitabine in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of GTI-2040 and gemcitabine in&#xD;
      treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy,&#xD;
      such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth and by making tumor cells more sensitive to gemcitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Primary I. Determine the toxicity profile and maximum tolerated dose of GTI-2040&#xD;
      and gemcitabine in patients with metastatic or unresectable solid tumors.&#xD;
&#xD;
      Secondary I. Determine the pharmacokinetics and pharmacodynamics of this regimen in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all&#xD;
      subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on&#xD;
      days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, 10 additional patients are treated at that dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-40 patients will be accrued for this study within 6-20&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0</measure>
    <time_frame>Up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, graded according to the NCI CTC v3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of gemcitabine triphosphate (dFdCTP) in terms of pharmacokinetics of gemcitabine hydrochloride</measure>
    <time_frame>Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of ribonucleotide reductase R2 and protein expression</measure>
    <time_frame>Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)</time_frame>
    <description>Student t-tests will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of apoptotic markers and cell cycle regulatory proteins</measure>
    <time_frame>Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)</time_frame>
    <description>Student t-tests will be employed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (GTI-2040, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GTI-2040</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (GTI-2040, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (GTI-2040, gemcitabine hydrochloride)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (GTI-2040, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (GTI-2040, gemcitabine hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor&#xD;
&#xD;
               -  Metastatic or unresectable disease for which standard curative or palliative&#xD;
                  measures do not exist or are no longer effective&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known active or progressive brain metastases or primary brain tumors&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN (5 times ULN if hepatic metastases are present)&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to study drugs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other condition (e.g., dementia or developmental delay) that would preclude giving&#xD;
             informed consent&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  Prior gemcitabine allowed&#xD;
&#xD;
          -  Prior investigational chemotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin, carmustine, or&#xD;
             nitrosoureas) and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent hormonal therapy (e.g., luteinizing hormone-releasing hormone agonists) for&#xD;
             prostate cancer is allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent long-term oral anticoagulation therapy (e.g., warfarin)&#xD;
&#xD;
               -  Prophylactic warfarin to maintain central venous access patency allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Takimoto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Therapy and Research Center at The UT Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at The UT Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

